$1.26
0.80% yesterday
Nasdaq, Nov 28, 06:57 pm CET
ISIN
US03836J1025
Symbol
APRE

Aprea Therapeutics Inc Stock price

$1.25
-0.09 6.72% 1M
-0.42 25.15% 6M
-2.04 62.01% YTD
-1.72 57.91% 1Y
-6.16 83.13% 3Y
-478.75 99.74% 5Y
-408.75 99.70% 10Y
-408.75 99.70% 20Y
Nasdaq, Closing price Wed, Nov 26 2025
+0.04 3.31%
ISIN
US03836J1025
Symbol
APRE
Industry

Key metrics

Basic
Market capitalization
$7.9m
Enterprise Value
$-5.8m
Net debt
positive
Cash
$13.7m
Shares outstanding
6.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
16.1 | 27.5
EV/Sales
negative | negative
EV/FCF
0.4
P/B
0.7
Financial Health
Equity Ratio
86.0%
Return on Equity
-62.9%
ROCE
-118.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$490.0k | $286.6k
EBITDA
$-13.8m | $-17.9m
EBIT
$-13.8m | $-16.5m
Net Income
$-13.0m | $-9.3m
Free Cash Flow
$-13.5m
Growth (TTM | estimate)
Revenue
-62.6% | -80.9%
EBITDA
6.4% | -24.8%
EBIT
6.5% | -15.2%
Net Income
3.4% | 28.6%
Free Cash Flow
2.0%
Margin (TTM | estimate)
Gross
-
EBITDA
-2,826.3% | -6,227.8%
EBIT
-2,830.2%
Net
-2,670.8% | -3,227.3%
Free Cash Flow
-2,763.2%
More
EPS
$-2.0
FCF per Share
$-2.3
Short interest
1.1%
Employees
8
Rev per Employee
$190.0k
Show more

Is Aprea Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Aprea Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Aprea Therapeutics Inc forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Aprea Therapeutics Inc forecast:

Buy
88%
Hold
13%

Financial data from Aprea Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
0.49 0.49
63% 63%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.91 5.91
16% 16%
1,206%
- Research and Development Expense 8.39 8.39
7% 7%
1,712%
-14 -14
6% 6%
-2,816%
- Depreciation and Amortization 0.02 0.02
33% 33%
4%
EBIT (Operating Income) EBIT -14 -14
6% 6%
-2,820%
Net Profit -13 -13
3% 3%
-2,661%

In millions USD.

Don't miss a Thing! We will send you all news about Aprea Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aprea Therapeutics Inc Stock News

Neutral
GlobeNewsWire
16 days ago
APR-1051 (WEE1 kinase inhibitor): In ongoing Phase 1 ACESOT-1051dose-escalation trial, 3 out of 4 patients at Dose Level 6 (100 mg once daily) achieved stable disease, per RECIST v1.1, in heavily pretreated gastrointestinal and gynecologic malignancies ATRN-119 (ATR kinase Inhibitor): RP2D of 1,100 mg once daily identified in ABOYA-119 dose-escalation study Posters on APR-1051 and ATRN-119 feat...
Neutral
GlobeNewsWire
about one month ago
DOYLESTOWN, Pa., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today provided an update on the ongoing Phase 1 ACESOT-1051 (A Multi-Center Evaluation of WEE1 Inhibitor in P...
Neutral
GlobeNewsWire
about one month ago
ATRN-119 (ATR Inhibitor): RP2D of 1,100 mg once daily identified in ongoing ABOYA-119 dose-escalation study Further ATRN-119 monotherapy enrollment paused with strategic focus on high-value combination Company is prioritizing its lead program, WEE1 kinase inhibitor APR-1051 DOYLESTOWN, Pa., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a ...
More Aprea Therapeutics Inc News

Company Profile

Aprea Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wenji Bao in 2002 and is headquartered in Boston, MA.

Head office United States
CEO Oren Gilad
Employees 8
Founded 2002
Website www.aprea.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today